Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 252 for “"Drug Conjugates"”.

  1. Computational Systems Pharmacology of Antibody-Drug Conjugates

    … as targeted cancer therapeutics, antibody-drug conjugates (ADCs) comprise a monoclonal antibody base attached to one or more cytotoxic agents via chemical linkers. This strategy enables specific targeting of antigens expressed on the cancer cell surface, resulting in receptor-mediated …

    jhu Repository record for Computational Systems Pharmacology of Antibody-Drug Conjugates (opens in a new tab)

  2. Cathepsin B cleavable antibody drug conjugates (ADCs) and betabody drug conjugates (BDCs) targeting phosphatidylserine in the breast tumor microenvironment.

    … the discovery and development of novel antibody-drug conjugates (ADCs) and betabody-drug conjugates (BDCs) to achieve targeted delivery of anti-cancer agents within the breast tumor microenvironment. The ADCs under development utilize bavituximab, a well-established antibody that targets …

    baylor Repository record for Cathepsin B cleavable antibody drug conjugates (ADCs) and betabody drug conjugates (BDCs) targeting phosphatidylserine in the breast tumor microenvironment. (opens in a new tab) Embargoed until 2030-12-15

  3. Peptide-Drug Conjugates for Improved Treatment of Diseases

    … past three decades, a variety of carrier-based drug delivery systems have been developed, aiming to achieve effective chemotherapy for cancer patients. The delivery vehicles are designed to satisfy some basic requirements, such as improved drug solubility, prodrug stability, responses to …

    jhu Repository record for Peptide-Drug Conjugates for Improved Treatment of Diseases (opens in a new tab)

  4. Novel approach cathepsin S-Specific antibody-drug conjugates

    … stage, where chemotherapy is limited. Antibody-drug conjugates (ADCs) offer targeted delivery of cytotoxic agents, reducing systemic toxicity. However, current ADCs face issues such as non-specific linker cleavage and lysosomal entrapment. This project developed a novel ADC platform using a …

    qu-belfast Repository record for Novel approach cathepsin S-Specific antibody-drug conjugates (opens in a new tab) Embargoed until 2030-12-31

  5. Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates

    The use of cancer targeted antibody-drug conjugates aims to reduce the adverse affects of current therapies by selectively seeking and destroying tumor cells. Current systems employ targeted monoclonal antibodies conjugated to chemotoxins which have good cancer cell specificity, but suffer from …

    washington Repository record for Intracellular Delivery of Cancer-Targeting Antibody-Drug Conjugates (opens in a new tab)

  6. DRUG-CONJUGATES FOR SELF-ASSEMBLED NANOPARTICLES IN ANTICANCER TREATMENT

    … anticancer compounds in order to form different drug-conjugates able to self-assemble in water to form nanoparticles. This approach is useful to improve the drug delivery properties and pharmacokinetic profile of anticancer drugs. All the described conjugates, except for the ones illustrated in …

    milano Repository record for DRUG-CONJUGATES FOR SELF-ASSEMBLED NANOPARTICLES IN ANTICANCER TREATMENT (opens in a new tab)

  7. ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.

    … emtansine (T-DM1) are anti-HER2 antibody-drug conjugates (ADCs) which have shown robust efficacy for treating breast cancer. For both ADCs, however, we lack effective biomarkers to predict outcomes from pre-treatment samples. Methods: To unveil predictive biomarkers for ADCs, we first …

    milano Repository record for ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER. (opens in a new tab)

  8. Synthesis and Analysis of Novel Antibody-Drug Conjugates (ADCs)

    Antibody-Drug Conjugates (ADCs) are a family of targeted therapeutic agents for the treatment of cancer. They consist of potent cytotoxic small molecules or biological toxins (i.e., the payload) and highly selective antibodies joined through cleavable or noncleavable linkers, thus combining the …

    kings Repository record for Synthesis and Analysis of Novel Antibody-Drug Conjugates (ADCs) (opens in a new tab) Embargoed until 2027-01-01

  9. Peptide-Drug Conjugates: From Supramolecular Polymers to Covalent Polymeric Networks

    … work in this thesis focuses on designing peptide drug conjugates as a versatile, multifunctional drug delivery system to address diverse therapeutic issues. Supramolecular polymers generated by the accumulation of individually weak non-covalent interactions possess a distinct linear release …

    jhu Repository record for Peptide-Drug Conjugates: From Supramolecular Polymers to Covalent Polymeric Networks (opens in a new tab) Embargoed until 2026-12-01

  10. GLUCOSE DENDRIMER–DRUG CONJUGATES FOR NEUROINFLAMMATORY PAIN AND NEUROPSYCHIATRIC APPLICATIONS

    … contribute to the potential of dendrimers in drug delivery. These include the ability to synthesize dendrimers with defined structures, with sizes at the nano level, and with tunable surface chemistry. Compared to other nanoparticles (metal NPs, LNPs etc), dendrimers have high reproducibility, …

    jhu Repository record for GLUCOSE DENDRIMER–DRUG CONJUGATES FOR NEUROINFLAMMATORY PAIN AND NEUROPSYCHIATRIC APPLICATIONS (opens in a new tab)

  11. Lysine-lysine‒based enzymatically cleavable linkers for antibody-drug conjugates

    Antibody-drug conjugates (ADCs) are a class of hybrid drugs comprised of an antibody and a covalently linked cytotoxic drug. ADCs are a promising cancer treatment due to the high specificity and affinity of antibodies to recognize cancer-associated receptors, delivering a cytotoxic drug into the …

    sask Repository record for Lysine-lysine‒based enzymatically cleavable linkers for antibody-drug conjugates (opens in a new tab)

  12. Pharmacokinetic Strategies to Enhance the Selectivity of Antibody-Drug Conjugates

    … of CPT, the use of monoclonal antibody-drug conjugates (i.e., ADCs) to actively target cancer cells has proven to be particularly successful. Two ADCs that deliver CPT: trastuzumab deruxtecan (T-DXd, Enhertu®) and sacituzumab govitecan (Trodelvy®), have been approved globally. However, …

    buffalo Repository record for Pharmacokinetic Strategies to Enhance the Selectivity of Antibody-Drug Conjugates (opens in a new tab)

  13. Development of analytical methods for determining metabolic stability of antibody drug conjugates

    Antibody drug conjugates deliver a cytotoxic payload to tumour cells, but only if the conjugate stays intact in blood. Payload lost early lowers the tumour dose and exposes healthy tissue to free drug. This thesis developed methods for measuring the metabolic stability of drug conjugates and built …

    kent Download PDF for Development of analytical methods for determining metabolic stability of antibody drug conjugates (opens in a new tab)

  14. SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN

    … of modern anticancer chemotherapy. However, many drugs do not selectively localize into solid tumors, as they normally accumulate also in healthy organs (e.g. liver and kidney). As a result, severe side effects are caused by the suboptimal biodistribution profile, in combination with the …

    milano Repository record for SYNTHESIS OF NEW RGD PEPTIDOMIMETIC-DRUG CONJUGATES TARGETING ΑVΒ3 INTEGRIN (opens in a new tab)

  15. Pharmacokinetics-Pharmacodynamics Based Investigations to Support the Development of Antibody-Drug Conjugates

    Antibody-drug Conjugates (ADCs) are one of the fastest growing class of anticancer therapeutics, which consists of monoclonal antibodies (mAbs) covalently bound to highly potent chemotherapeutic agents (payloads) via chemical linkers. Selective delivery of payloads to antigen-overexpressing tumor …

    buffalo Repository record for Pharmacokinetics-Pharmacodynamics Based Investigations to Support the Development of Antibody-Drug Conjugates (opens in a new tab)

  16. Design and generation of antibody-drug conjugates using non-canonical amino acids

    Antibody-drug conjugates are cancer therapeutics that combine specificity and toxicity through the antibody and its conjugated drug, respectively. Due to their unique structures and chemical functions, non-canonical amino acids enable tailor-made designs of protein conjugates and their generation …

    fu-berlin Repository record for Design and generation of antibody-drug conjugates using non-canonical amino acids (opens in a new tab)

Page 1 of 13